Risk stratification in myelodysplastic syndromes: Is there a role for gene expression profiling?

Amer M. Zeidan, Thomas Prebet, Ehab Saad Aldin, Steven David Gore

Research output: Contribution to journalArticle

Abstract

Patients with myelodysplastic syndromes (MDS) exhibit wide heterogeneity in clinical outcomes making accurate risk-stratification an integral part of the risk-adaptive management paradigm. Current prognostic schemes for MDS rely on clinicopathological parameters. Despite the increasing knowledge of the genetic landscape of MDS and the prognostic impact of many newly discovered molecular aberrations, none to date has been incorporated formally into the major risk models. Efforts are ongoing to use data generated from genome-wide high-throughput techniques to improve the 'individualized' outcome prediction for patients. We here discuss an important paper in which gene expression profiling (GEP) technology was applied to marrow CD34+ cells from 125 MDS patients to generate and validate a standardized GEP-based prognostic signature.

Original languageEnglish (US)
Pages (from-to)191-194
Number of pages4
JournalExpert review of hematology
Volume7
Issue number2
DOIs
StatePublished - Apr 2014

Keywords

  • Gene expression profiling
  • international prognostic scoring system
  • myelodysplastic syndromes
  • prognostication
  • risk stratification

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Risk stratification in myelodysplastic syndromes: Is there a role for gene expression profiling?'. Together they form a unique fingerprint.

  • Cite this